Different Omega-3 Formulations Yield to Diverse Clinical Response: A Case-Report

Title:Different Omega-3 Formulations Yield to Diverse Clinical Response: A Case-Report

Volume: 11 Issue: 2

Author(s): Luca Gallelli, Andzelika Michniewicz, Roberta Stefanelli, Roberto Cannataro, Paola Longo, Mariarita Perri, Erika Cione and Maria C. Caroleo

Affiliation:

Keywords: Omega-3 formulation, clinical efficacy, clinical inefficacy, dissolution time.

Abstract: Treatment guidelines recommend omega-3 with Docosahexaenoic Acid (DHA) and Eicosapentaenoic Acid (EPA) content not above 85% in patients with high plasma levels of triglycerides. Since the different up to date formulation of omega-3 available in commerce must be similar to clinical efficacy and safety, herein, we report the case a 52-year-old woman who presented clinical inefficacy using Olevia^® omega-3 treatment. Clinical evaluation excluded the presence of intestinal or systemic diseases able to reduce the drug absorption. Switching the therapy from (Olevia^®) to an equivalent omega-3 formulation (Esapent^®), we documented a decrease in her plasma triglycerides levels. In order to evaluate a possible difference between these formulations we performed a single blind in vitro dissolution test using three pills for each formulation of omega-3 (Olevia^®, Esapent® and another one chosen between the several formulations available in commerce: DOC Generic^®) that revealed a significant difference (>20%) in the dissolution time of three different omega- 3 commercially available drug formulation.

Cite this article as:

Gallelli Luca, Michniewicz Andzelika, Stefanelli Roberta, Cannataro Roberto, Longo Paola, Perri Mariarita, Cione Erika and C. Caroleo Maria, Different Omega-3 Formulations Yield to Diverse Clinical Response: A Case-Report, Current Drug Safety 2016; 11 (2) . https://dx.doi.org/10.2174/1574886311666151106120928